weight regain?obesity memory
Conditions
Interventions
Sponsors
The Second Hospital, University of South China
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years old, regardless of gender; 2. With a definite history of obesity (previous BMI >= 28 kg/m²), and having achieved weight loss through dietary control, exercise intervention, medication (excluding weight-loss drugs) or surgical treatment within the past 6 months, with the weight loss range reaching at least 5% of the initial body weight (i.e., (initial body weight - current body weight)/initial body weight × 100% >= 5%); 3. Free from severe organic diseases of the heart, liver, kidneys, etc. (e.g., heart failure, liver cirrhosis, chronic renal failure); 4. No history of malignant tumors, autoimmune diseases or mental illnesses; 5. No use of metabolism-affecting drugs (e.g., insulin, glucocorticoids, weight-loss drugs) within the past 3 months; 6. Voluntarily sign the informed consent form and be able to cooperate with the completion of 18-month follow-up and sample collection. Normal weight group: 1. Age range of 18-60 years old, gender not limited; 2. No history of obesity (with a consistent previous BMI < 24 kg/m²), stable body weight within the past 5 years (fluctuation < 5%), and current BMI 18.5-23.9 kg/m². 3. Other standards are the same as 3-6 for the weight rebound group.
Exclusion criteria
Exclusion criteria: 1. Having participated in other interventional clinical studies (including drug/medical device/biologic trials) within 3 months prior to enrollment; or having a history of blood donation, massive blood loss (> 400 mL) within 3 months; or having used any medications within 30 days; or being an alcoholic (consuming more than 14 alcohol units per week) within 6 months; or being unwilling to abstain from alcohol-containing products during the study period; or having a positive breath alcohol test (> 0.0 mg/100 mL); 2. Having major systemic diseases with current clinical significance, including diseases of the circulatory system (e.g., coronary heart disease, hypertension of Grade ? or higher), metabolic and endocrine system (e.g., diabetes mellitus), urinary system (e.g., chronic kidney disease [CKD] Stage 3 or higher), nervous system (e.g., epilepsy), immune system (e.g., immunodeficiency, autoimmune diseases), hematological system, respiratory system, and mental disorders; 3. Having a diagnosis of dementia, or a Mini-Mental State Examination (MMSE) score of < 24; or having cognitive/language impairments or low educational level resulting in inability to read or write, which affects cognitive assessment and communication; or being complicated with diseases that cause decreased cognitive, visual, auditory, or language comprehension abilities (e.g., acute stroke, intracranial tumors, Alzheimer's disease); 4. Failure to meet the renal function criteria: creatinine clearance rate (CCr) < 80 mL/min calculated by the Cockcroft-Gault formula (serum creatinine must be measured via standardized testing); 5. Having clinically significant abnormalities identified at enrollment, as determined by the researcher—including abnormal physical examination findings, pathological changes on electrocardiogram (ECG), laboratory test values exceeding the normal range by more than 20%, significant abnormalities on ultrasound/radiological imaging, and vital signs persistently deviating from baseline values; 6. Having diseases of the musculoskeletal system (e.g., osteoarthritis, bone fractures) that prevent completion of motor tasks, or diseases of other systems that affect cognitive and motor functions; or being unable to tolerate venipuncture, having a history of hematophobia/needle phobia, or having obvious bleeding/coagulation disorders; 7. Having undergone surgical procedures within 3 months prior to enrollment, or having plans to undergo surgical procedures during the study period; 8. Having implanted devices (e.g., cardiac pacemakers, cochlear implants, steel screws, plates) in the body, or suffering from claustrophobia, which makes the subject unsuitable for magnetic resonance imaging (MRI) scans; 9. Participation is involuntary, or the subject has not signed the informed consent form (ICF); 10. After comprehensive assessment by the research team, the subject has special circumstances that may affect the integrity of the study or the subject’s safety, or researchers determine that the subject is unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight;height;metabolic indicators;inflammatory indicators;Intestinal barrier function indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| waist circumference; | — |
Countries
China
Contacts
Public ContactJiang Tao
The Second Hospital, University of South China
Outcome results
None listed